The breast and ovarian cancer susceptibility genes *BRCA1*and *BRCA2*were identified over 10 years ago. Development and expansion of cancer genetics services across the United Kingdom coupled with advances in genetic technology and investment from the government White Paper \'Our Inheritance, Our Future\' have increased demand and access for diagnostic genetic testing of *BRCA1*and *BRCA2*. NICE guidelines from 2004 recommend that individuals with a \> 20% risk of having a mutation should be offered comprehensive diagnostic *BRCA1*and *BRCA2*mutation testing. This now detects over 95% of all mutations, as well as variants of unknown significance. *BRCA1*and *BRCA2*carriers face complex decisions regarding screening and risk-reducing options in a rapidly changing field and may benefit from a multidisciplinary approach to their care. However, the majority of breast-cancer-only families will have no *BRCA1*or *BRCA2*mutation identified on diagnostic gene testing. Research studies to identify further breast cancer susceptibility genes are ongoing.
